Vera Therapeutics CEO sells 18,500 shares
Vera Therapeutics, Inc. director, president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A Common Stock on June 23, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vera Therapeutics, Inc. director, president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A Common Stock on June 23, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026, with individual trades occurring between $37.43 and $38.315. After the sales, Fordyce directly holds 198,244 shares and indirectly holds 99,081 shares through a trust and 122,949 shares through a GRAT.
Insider Trade Summary 10b5-1
Net Seller: 18,500 shares
Net Sell
4 txns
Insider
Fordyce Marshall
Role
PRESIDENT AND CEO
Sold
18,500 shs ($702K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 18,412 | $37.9311 | $698K |
| Sale | Class A Common Stock | 88 | $38.43 | $3K |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 198,244 shares (Direct);
Class A Common Stock — 122,949 shares (Indirect, By GRAT);
Class A Common Stock — 99,081 shares (Indirect, By Trust)
Footnotes (2)
- F1. This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Key Figures
Shares sold: 18,500 shares
Sale price 1: $38.43 per share
Sale price 2: $37.9311 per share
+5 more
8 metrics
Shares sold
18,500 shares
Total Class A Common Stock sold on June 23, 2026
Sale price 1
$38.43 per share
Weighted-average price for 88 shares sold
Sale price 2
$37.9311 per share
Weighted-average price for 18,412 shares sold
Direct holdings after sale
198,244 shares
Direct Class A Common Stock held following transactions
Trust holdings
99,081 shares
Indirect holdings classified as By Trust
GRAT holdings
122,949 shares
Indirect holdings classified as By GRAT
10b5-1 plan adoption date
January 9, 2026
Date CEO’s Rule 10b5-1(c) trading plan was adopted
Price range
$37.43–$38.315
Range of individual trade prices within reported sale
Key Terms
Rule 10b5-1(c), weighted-average price, GRAT, Class A Common Stock, +1 more
5 terms
Rule 10b5-1(c) regulatory
"written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted-average price financial
"The price reported is a weighted-average price. These shares were sold in multiple transactions"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
GRAT financial
"total_shares_following_transaction: 122949.0000, direct_or_indirect: I, nature_of_ownership: By GRAT"
Class A Common Stock financial
"security_title: Class A Common Stock, transaction_type: non-derivative"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
open-market sale financial
"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Vera Therapeutics (VERA) report for Marshall Fordyce?
Vera Therapeutics reported that CEO Marshall Fordyce sold 18,500 shares of Class A Common Stock in open-market transactions. These sales occurred on June 23, 2026, and are disclosed in a Form 4 insider trading report filed with regulators.
What does the weighted-average price disclosure mean in the Vera Therapeutics (VERA) Form 4?
The filing states the reported prices are weighted averages because shares were sold in multiple trades at different prices. It also notes that detailed trade-by-trade pricing, between $37.43 and $38.315, is available to regulators and shareholders on request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
